<DOC>
	<DOCNO>NCT01552980</DOCNO>
	<brief_summary>This open-label , phase II study evaluate efficacy safety modify regimen oxaliplatin S-1 unresectable gastric adenocarcinoma first-line therapy .</brief_summary>
	<brief_title>Efficacy Safety Study Modified SOX Regimen First-Line Treatment Unresectable Gastric Adenocarcinoma</brief_title>
	<detailed_description>Primary endpoint : Overall Response Rate Secondary endpoint : Time progression , overall survival , safety data</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Signed write informed consent ; Patients histologically cytologically confirm unresectable gastric adenocarcinoma whose ECOG performance status 02 ; Presence measurable disease radiographic study ( include CT MRI scan , chest xray ) physical examination ; At least 3 week since last major surgery ; At least 12 month since last adjuvant chemotherapy ; At least 6 week since prior radiotherapy provide extent site radiotherapy field mark bone marrow suppression NOT expect ; Patients receive palliative radiotherapy must recover reversible toxic effect e.g . nausea vomit cause radiation field ; Patients reproductive potential must use effective BC ; Required Screening Laboratory Criteria : Hemoglobin 90g/L WBC 3.5 x 109/L Neutrophils 1.5 x 109/L Platelets 100 x 109/L Creatinine 133 umol/L creatinine clearance 60 mL/min A probable life expectancy least 6 month ; Brain metastasis ; Female childbearing potential , pregnancy test positive ; Concomitant malignancies previous malignancy colorectal cancer within last five year , exception adequately treat basal squamous cell carcinoma skin , carcinoma situ cervix , low grade prostate cancer ; Active infection ; Concurrent severe medical problem unrelated malignancy , would significantly limit full compliance study expose patient extreme risk ; Sexually active patient refuse practice adequate contraception ; Patients condition might affect absorption oral drug ( example intermittent obstruction ) unless discuss agreed principal investigator ; History grade 3 4 toxicity fluoropyrimidines ; Preexisting neuropathy â‰¥ NCI CTC grade 2 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Gastric cancer</keyword>
	<keyword>Adenocarcinoma</keyword>
	<keyword>SOX</keyword>
</DOC>